This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04967/identifier/drugbank/
n19http://linked.opendata.cz/resource/mesh/concept/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04967/identifier/chemspider/
n7http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB04967/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB04967/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB04967/identifier/wikipedia/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04967/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04967/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB04967/identifier/pubchem-substance/

Statements

Subject Item
n2:DB04967
rdf:type
n3:Drug
n3:description
One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.
n3:generalReferences
# Luo M, Kelley MR: Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res. 2004 Jul-Aug;24(4):2127-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15330152 # Del Rowe JD, Bello J, Mitnick R, Sood B, Filippi C, Moran J, Freeman K, Mendez F, Bases R: Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):89-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9989518
n3:group
approved investigational
n3:indication
Intended for use as a radiation sensitizer in the treatment of brain cancer.
owl:sameAs
n6:DB04967 n7:DB04967
dcterms:title
Lucanthone
adms:identifier
n9:C11715 n10:10180 n11:9772 n12:DB04967 n13:46507260 n15:51052 n16:PA164748783 n17:Lucanthone
n3:mechanismOfAction
Recent data suggests that lucanthone inhibits post-radiation DNA repair in tumor cells. The ability of lucanthone to inhibit AP endonuclease and topoisomerase II probably account for the specific DNA repair inhibition in irradiated cells.
n3:synonym
Lucanthonum Lucantona 1-{[2-(diethylamino)ethyl]amino}-4-methylthioxanthen-9-one 1-diethylaminoethylethylamino-4-methyl-thioxanthenone 1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one Lucanthone
n3:salt
n18:hasConcept
n19:M0012715
n3:IUPAC-Name
n4:271B6179-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B617F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B617E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B617B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B617C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B617D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6177-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6178-363D-11E5-9242-09173F13E4C5 n4:271B6175-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6176-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6185-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6186-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6180-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6181-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6183-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6182-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6184-363D-11E5-9242-09173F13E4C5
n3:absorption
Orally available
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
479-50-5
n3:category
n3:Bioavailability
n4:271B618B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B618D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B618E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B618A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6189-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B618C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B617A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6187-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6188-363D-11E5-9242-09173F13E4C5